Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sorting nexin-29 (SNX29) is a member of the sorting nexin (SNX) protein family, characterized by the presence of a phosphoinositide-binding PX domain that enables association with phosphatidylinositol-enriched membranes of the endosomal network[2]. SNX29 is categorized within the SNX-PX subfamily, which includes SNX proteins containing only the PX domain and is evolutionarily conserved among eukaryotes[2]. SNX proteins, in general, regulate endocytosis and the sorting of membrane protein cargoes through endosomal and lysosomal pathways, coordinating protein recycling or degradation. SNX29 itself has been associated with diverse biological processes and disease roles, such as growth and myogenesis in animals, psychiatric conditions (schizophrenia, autism), certain cancers, and immune function (IgA levels), mainly through observational and genetic studies[1]. In livestock, SNX29 gene copy number variation influences growth traits, making it an important molecular marker for breeding but not a direct therapeutic target. No drugs are known to directly interact with SNX29, nor is there an established therapeutic mechanism of action or notable human toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorting nexin-29 (SNX29).